[go: up one dir, main page]

MA34458B1 - Combinaisons comprenant des antipsychotiques atypiques et des agonistes de tarr1 - Google Patents

Combinaisons comprenant des antipsychotiques atypiques et des agonistes de tarr1

Info

Publication number
MA34458B1
MA34458B1 MA35646A MA35646A MA34458B1 MA 34458 B1 MA34458 B1 MA 34458B1 MA 35646 A MA35646 A MA 35646A MA 35646 A MA35646 A MA 35646A MA 34458 B1 MA34458 B1 MA 34458B1
Authority
MA
Morocco
Prior art keywords
tarr1
agonists
combinations
atypical antipsychotics
receptor
Prior art date
Application number
MA35646A
Other languages
English (en)
Inventor
Marius Hoener
Susanne Raab
Celine Risterucci
Sabine Sewing
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34458(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34458B1 publication Critical patent/MA34458B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique destinée au traitement de la schizophrénie et des épisodes maniaques aigus associés aux troubles bipolaires, qui comprend un composé actif sur un récepteur TAAR1 (récepteur associé à une amine de trace 1) et un médicament antipsychotique. De manière surprenante, une telle combinaison s'est avérée réduire les effets secondaires métaboliques qui se produisent lors de l'utilisation d'un antipsychotique seul.
MA35646A 2010-08-02 2011-07-26 Combinaisons comprenant des antipsychotiques atypiques et des agonistes de tarr1 MA34458B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10171560 2010-08-02
PCT/EP2011/062772 WO2012016879A1 (fr) 2010-08-02 2011-07-26 Combinaisons comprenant des antipsychotiques atypiques et des agonistes de tarr1

Publications (1)

Publication Number Publication Date
MA34458B1 true MA34458B1 (fr) 2013-08-01

Family

ID=44512842

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35646A MA34458B1 (fr) 2010-08-02 2011-07-26 Combinaisons comprenant des antipsychotiques atypiques et des agonistes de tarr1

Country Status (25)

Country Link
US (2) US9132136B2 (fr)
EP (1) EP2600853A1 (fr)
JP (2) JP5749802B2 (fr)
KR (1) KR101455548B1 (fr)
CN (1) CN103068379A (fr)
AR (1) AR082458A1 (fr)
AU (1) AU2011287701A1 (fr)
BR (1) BR112013002518A2 (fr)
CA (1) CA2802935A1 (fr)
CL (1) CL2013000313A1 (fr)
CO (1) CO6761298A2 (fr)
CR (1) CR20120663A (fr)
EA (1) EA024703B1 (fr)
EC (1) ECSP13012414A (fr)
MA (1) MA34458B1 (fr)
MX (1) MX340489B (fr)
MY (1) MY166955A (fr)
NZ (1) NZ604592A (fr)
PE (1) PE20130497A1 (fr)
PH (1) PH12013500043A1 (fr)
SG (1) SG187125A1 (fr)
TW (1) TWI511728B (fr)
UA (1) UA112527C2 (fr)
WO (1) WO2012016879A1 (fr)
ZA (1) ZA201300431B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2890438B2 (ja) 1989-02-16 1999-05-17 東陶機器株式会社 流量制御ノズル
JP3072762B2 (ja) 1989-02-16 2000-08-07 東陶機器株式会社 流量制御ノズル
US8802673B2 (en) * 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
RU2621050C2 (ru) 2012-01-12 2017-05-31 Ф. Хоффманн-Ля Рош Аг Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
SG11201503573WA (en) * 2012-11-16 2015-06-29 Hoffmann La Roche Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
RU2677328C1 (ru) 2013-12-11 2019-01-16 Ф. Хоффманн-Ля Рош Аг Способ получения хиральных 2-арилморфолинов
WO2015165085A1 (fr) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Dérivés de morpholine-pyridine
US10858326B2 (en) * 2016-05-04 2020-12-08 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
JP7453148B2 (ja) 2018-02-16 2024-03-19 サノビオン ファーマシューティカルズ インク 塩、結晶形態、およびその製造方法
AU2019255310B2 (en) 2018-04-18 2022-11-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3797108B1 (fr) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulateurs de l'enzyme méthyl modifiant, compositions et leur utilisation.
EP4003532B1 (fr) 2019-07-24 2024-09-04 Constellation Pharmaceuticals, Inc. Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
MX2022009771A (es) * 2020-02-07 2022-08-25 Cytokinetics Inc Moduladores de nampt.
JP7781768B2 (ja) 2020-04-14 2025-12-08 スミトモ・ファーマ・アメリカ・インコーポレイテッド 神経学的および精神障害の治療方法
KR20230005888A (ko) * 2020-05-09 2023-01-10 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
EP4317164A4 (fr) * 2021-03-29 2024-07-31 Shujing Biopharma Co., Ltd Dérivé contenant un spiro, son procédé de préparation et son utilisation
CN114288304A (zh) * 2021-12-31 2022-04-08 江苏海洋大学 一种抗精神分裂症组合物及其应用
AR129909A1 (es) 2022-07-15 2024-10-09 Hoffmann La Roche Cetorreductasa mutante con mayor actividad de cetorreductasa así como métodos y usos de esta

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1838716T3 (da) 2005-01-05 2011-07-25 Lilly Co Eli Olanzapinpamota-dihydrat
PL385455A1 (pl) * 2005-04-22 2008-11-24 Teva Pharmaceuticals Usa,Inc. Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
KR20070022539A (ko) 2005-08-22 2007-02-27 홍진표 지프라시돈 또는 그의 대사산물을 함유하는 항비만 조성물
CA2675221C (fr) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc
EP2121641B1 (fr) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines comme ligands de taar1
BRPI0815038A2 (pt) 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
PE20110215A1 (es) 2008-07-24 2011-03-31 Hoffmann La Roche Derivados de 4,5-dihidro-oxazol-2-ilo
NZ590951A (en) 2008-08-05 2012-09-28 Omeros Corp Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8293954B2 (en) * 2010-03-10 2012-10-23 Honeywell International Inc. Catalyst life improvement for the vapor phase manufacture of 1-chloro-3,3,3-trifluoropropene

Also Published As

Publication number Publication date
PH12013500043A1 (en) 2019-06-03
UA112527C2 (uk) 2016-09-26
KR101455548B1 (ko) 2014-10-27
EA201291476A1 (ru) 2013-06-28
MX2013000745A (es) 2013-03-05
EA024703B1 (ru) 2016-10-31
KR20130070629A (ko) 2013-06-27
US9132136B2 (en) 2015-09-15
TWI511728B (zh) 2015-12-11
PE20130497A1 (es) 2013-04-22
JP2013536181A (ja) 2013-09-19
ZA201300431B (en) 2013-09-25
ECSP13012414A (es) 2013-03-28
CR20120663A (es) 2013-04-01
EP2600853A1 (fr) 2013-06-12
BR112013002518A2 (pt) 2016-05-31
CO6761298A2 (es) 2013-09-30
MX340489B (es) 2016-07-11
TW201206912A (en) 2012-02-16
NZ604592A (en) 2015-02-27
WO2012016879A1 (fr) 2012-02-09
JP5749802B2 (ja) 2015-07-15
CA2802935A1 (fr) 2012-02-09
CN103068379A (zh) 2013-04-24
AU2011287701A1 (en) 2013-01-10
US20130345201A1 (en) 2013-12-26
MY166955A (en) 2018-07-25
US20120028964A1 (en) 2012-02-02
AR082458A1 (es) 2012-12-12
SG187125A1 (en) 2013-02-28
CL2013000313A1 (es) 2013-05-03
JP2015145408A (ja) 2015-08-13

Similar Documents

Publication Publication Date Title
MA34458B1 (fr) Combinaisons comprenant des antipsychotiques atypiques et des agonistes de tarr1
NI201100068A (es) Combinación de una insulina y un agonista de glp-1.
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
MA39784B1 (fr) Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
MY167560A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
BR112014013788A8 (pt) portador de seringa
BR112014013759A8 (pt) portador de seringa
EA201170676A1 (ru) Агонисты рецептора меланокортина
CO6210723A2 (es) Combinaciones de benzotiazolona agonista de receptores adrenergicos beta 2
MA38096B1 (fr) Solutions mydriatiques et anti-inflammatoires stables sans agents de conservation destinees a etre injectees
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA38147A1 (fr) Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
MA41634B1 (fr) Formulation à base de combinaison de tésofensine et de métoprolol
MA39164A1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
MA32763B1 (fr) Composition vétérinaire antiprolactinique destinés aux ruminants
GT200500246A (es) Combinacion de compuestos organicos
EA202091356A1 (ru) A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ
PE20120515A1 (es) Formulaciones de deferiprona
MY161655A (en) Unit dosage of apadenoson
MX2009010455A (es) Lisina protegida en el rumen.
TH154737A (th) สารรวมซึ่งประกอบรวมด้วยยารักษาโรคจิตชนิดนอกแบบ (atypical antipsychotics) และ taar1 อะโกนิสต์ (taar1 agonists)
MA46669B1 (fr) Re-stimulation de lymphocytes infiltrant les tumeurs cryoconservés
MA38636A1 (fr) Composés de 3,4-dihydroisoquinoléin-2(1h)-yle
UA108990C2 (en) THE APPLICATION OF 4-AMINO-PIRIDIN NORRELIVER IN CREATIVE CREATIVES IN CANCER CANCER